AI-powered sports centre Airena hopes to use technology to help young basketballers grow
Russel Low, head coach of Project 95 Basketball Academy, making a slam dunk at the grand opening of Airena, an AI-powered sports centre, at Jalan Ampas. ST PHOTO: GIN TAY
SINGAPORE – With 10 cameras pointing at its basketball court at all times, newly opened sports centre Airena is equipped to capture movement data, which is used to analyse players' performance during training and matches.
The facility, which is located at Jalan Ampas off Balestier Road, officially opened on May 10, when guests were shown how artificial intelligence (AI) converts the data and gives coaches reports of their players, which can be viewed via an app.
Boasting smart tracking technology by Chinese company Qiuxiu, it offers real-time analytics in metrics such as strength, speed and reaction time.
Former Singapore Slinger Mitchell Folkoff, who is head coach of Project 95 Basketball Academy, speaking at the grand opening of Airena sports centre on May 10.
ST PHOTO: GIN TAY
Airena, which also has a gym, is also home of the Project 95 (P95) Basketball Academy, whose coaches are former national basketballers such as Mitchell Folkoff and Russel Low.
Speaking to the Sunday Times on the sidelines of the launch, Folkoff believes this AI-driven approach will help them take coaching to another level.
He said: 'How do you evaluate a player? There's no data to back up, like, what he's doing great, what he's not so good at… You only can see it through your set of eyes.
'And I think for us to take coaching to the next level, to catch up with the rest of the world, we have to implement all the analytics into our training, tracking, learning progression, and then into the games.
'What we're trying to do is to optimise how we can utilise this technology and help kids grow from it. And I think it's a great thing because it gives us something that's tangible, because basketball is transitioning to a very data-centric sport.'
With the usage of AI technology alongside conventional training, Folkoff is able to gain a deeper understanding of his players' condition and progress.
The real-time feedback has been useful for Kaiser Ng, whose sons, aged nine and 13, are enrolled with the P95 academy.
'As a parent, I like that P95 uses the AI capability at Airena to enhance the training programme by providing timely and objective feedback, and making the training more personalised,' said Ng.
'I believe it will accelerate skill development, and make learning the game more engaging and measurable.
'We are still learning how to take advantage of the AI technology that is available to us through the app and I hope our boys can use it to help them adjust the arc of their shots and to utilise their left hand more for dribbling and lay-ups.'
The Shootz app by Qiuxiu, an AI app that tracks athletes stats via the 10 cameras on court.
ST PHOTO: GIN TAY
Folkoff added that the AI is able to track statistics such as hit percentage, angle of shot trajectory, missed and made baskets, but added that it is still a language learning model.
Statistics may show that a player is leaning one way more than the other and the AI might suggest that they are more prone to injuries.
He added: 'The more data it collects, the more it can fine-tune the statistics and it will start to improve on the quality of the movement after it gets (the data) back.
'(We have received) pretty positive feedback on the AI aspect of training, because everyone loves videos, they love watching highlights and seeing analytics.
'The parents are actually quite futuristic with regards to the whole AI and how it can help develop their kids. We're living in a time where stats is a huge thing for kids, for parents… It's all about statistics.'
Alan Lim, director of Airena and P95 said: 'The basic step now is still visualisation and the kids see their own mistakes. That's where they improve a lot, and their general interests also spike up because they see themselves in action.
'AI data comes when you want to drive a point. Of course, traditional coaching means that moral values are already part of it.
'Airena is our first physical location. It's a showroom of top-tier technology and we're trying to build multiple locations such as this, to just grow the concept of what Airena is like and the ability to provide many aspects to basketball training.'
Melvyn Teoh is a sports journalist at The Straits Times.
Join ST's Telegram channel and get the latest breaking news delivered to you.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
5 hours ago
- Straits Times
Why China biotech is getting a DeepSeek moment too
Workers working at a Sinovac Covid-19 vaccine production line in Beijing in 2021. So far, the biotech industry is relatively insulated from Mr Trump's tariffs. PHOTO: XINHUA From artificial intelligence to military defence, China has offered a few DeepSeek moments in 2025 , showcasing that the country is more than just the world's biggest factory, and that it also can compete with the US on the technology front. Now biotech is having its own. In late May, Pfizer agreed to pay a record US$1.25 billion (S$1.6 billion) upfront to license an experimental cancer drug from Shenyang-based 3SBio, as well as making a US$100 million equity investment in the Hong Kong-listed biotech company. Two weeks later, Bristol Myers Squibb said it would pay BioNTech US$1.5 billion guaranteed to license a similar cancer asset. It was a win for BioNTech, which bought Biotheus, the Chinese company that developed the drug, late in 2024 for US$800 million. Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Times
12 hours ago
- Business Times
Why China biotech is getting a DeepSeek moment, too
FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the country is more than just the world's biggest factory, and that it also can compete with the United States on the technology front. Now biotech is having its own. In late May, Pfizer agreed to pay a record US$1.25 billion upfront to license an experimental cancer drug from Shenyang-based 3SBio, as well as making a US$100 million equity investment in the Hong Kong-listed biotech company. Two weeks later, Bristol-Myers Squibb said it would pay BioNTech US$1.5 billion guaranteed to license a similar cancer asset. It was a win for BioNTech, which bought Biotheus, the Chinese company that developed the drug, late last year for US$800 million. Increasingly, big pharmaceutical companies are seeing Chinese biotech as the disruptors. These two deals will allow Pfizer and Bristol-Myers Squib to go after Merck & Co's Keytruda, the world's top-selling medicine. 3SBio's drug works in the same way as a therapy from China's Akeso, which outperformed Keytruda in one trial. US-based Summit Therapeutics licensed Akeso's assets for US$500 million upfront in late 2022. Excitement These billion-dollar deals got bankers and investors excited. The Hang Seng Biotech Index is up about 60 per cent this year. By comparison, the S&P biotech index is down 6.5 per cent. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up There are good reasons to believe this rapid pace of dealmaking and enthusiasm for China biotech will last, with US President Donald Trump's economic policies serving as a major catalyst. Trump's threats to slash US prescription drug costs by '59 per cent, PLUS', as well as Medicaid and Medicare cuts in his big, beautiful tax and spending bill, will inevitably dent Big Pharma's bottom line. To cut in-house R&D expenses, these multinationals might have to come to China, where early-stage human tests are much cheaper and easier to run, despite comparable safety protocols. So far, the biotech industry is relatively insulated from Trump's tariffs, providing a meaningful safe haven for global investors. Rare earths materials and Boeing plane deliveries might be used as negotiation tools, but Beijing is making an exception for public health. It continues to welcome American-made medical supplies, including Pfizer's lung cancer drug Lorbrena and Merck's Gardasil, a HPV vaccine that protects against cervical cancer. Being in Beijing's good books allows Big Pharma to seal licensing deals with local partners. In addition, global drug companies and venture capital funds might want to take equity stakes too, just like Pfizer did last month. With a dip in biotech funding, especially in China, startups are unable to advance drugs on their own, and therefore demand large upfront licensing payments. This gives Western companies leverage to negotiate good deals. What is innovation without human talent? China's 'engineer dividend' is likely to pay off big time in the next few years, propelled by a hostile White House that vows to 'aggressively revoke' visas of Chinese studying in 'critical fields'. Already, the number of Chinese students in the US has dropped 22 per cent from its pre-pandemic peak, with many pointing to anti-Asian sentiment during Covid as a major drawback. Going forward, more could be forgoing US university degrees and working for promising startups at home instead. Between 2000 and 2020, the number of engineers in China ballooned from 5.2 million to 17.7 million, according to the State Council. The discipline and medicine are among the most popular fields for graduate studies. Those under the age of 30 account for 44 per cent of the total engineering pool, versus 20 per cent in the US, according to data compiled by Kaiyuan Securities. As a result, compensation for researchers is only about one-eighth that in the US. In other words, Chinese engineers are young, cheap and abundant. Tailwinds So what we've got are a lot of tailwinds: A group of strategic buyers eager to cut expenses and outsource research, a relatively benign local authority, and competitive talents. China's biotech industry is starting to dazzle. BLOOMBERG
Business Times
18 hours ago
- Business Times
Huawei launches Pura 80 smartphone series in next step of China comeback
[BEIJING] Chinese tech giant Huawei launched its Pura 80 smartphone series on Wednesday (Jun 11), as the company seeks to cement its comeback in China's premium smartphone market following years of US sanctions. Huawei's latest flagship launch demonstrates the Chinese tech giant's continued efforts to reclaim the top spot in its home market despite ongoing US sanctions. Each new phone release is closely watched as a barometre of the company's technological capabilities and market resilience following years of restrictions that severely impacted its smartphone business. Huawei's resurgence has intensified pressure on Apple, which has seen its market share in China steadily decline and has increasingly relied on price discounts to stimulate sales. Huawei unveiled the Pura 80 series through a livestream event, with consumer business unit head Yu Chengdong focusing heavily on camera capabilities and AI features while staying silent about the chips powering the devices. The series includes four models: Pura 80, Pura 80 Pro, Pura 80 Pro+, and Pura 80 Ultra. Pricing starts at 6,499 yuan (S$1,163) for the Pro series launching Jun 14, with the Pro+ also launching Jun 14 at 7,999 yuan and the Ultra at 9,999 yuan on Jun 26. The base model launches in July. The cameras use XMAGE technology and feature ultra-wide-angle and macro telephoto lenses with embedded AI that can identify objects and provide information like tourist guides. Huawei phone launches generate significant interest as many view them as the company defying US sanctions. On Chinese microblogging platform Weibo, three of the top ten trending topics on Wednesday were Pura 80-related. User reactions were mixed, with many praising the camera capabilities and sleek design while others complained the prices were too high and not worth the cost. REUTERS
